Advances in the Management of Bladder and Kidney Cancer

A MULTIDISCIPLINARY APPROACH

mskcc.org/urologycourse
The course objective is to advance and disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer. This will include insights into the ongoing cancer research in the field and at MSK.

The course objective is to advance and disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer.

The program will include comprehensive state-of-the-art lectures and discussions encouraging the exchange of ideas between faculty (radiologists, pathologists, surgeons, radiation oncologists, and medical oncologists) and the audience. Discussions will center on the multidisciplinary management of bladder and kidney cancer.

**Educational Objectives**

- To present a multidisciplinary approach to the management of bladder and kidney cancer including surgery, medical oncology, and radiation therapy.
- To advance and disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer.

**Target Audience**

The intended audience includes urologists, urologic-oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, and allied health professions.

**Live Simulcast Available**

We are pleased to offer a live simulcast option for this course. CME and ABIM MOC credit is offered for the live simulcast and active participation is required throughout the course.

[mskcc.org/urologycourse](http://mskcc.org/urologycourse)
### COURSE FACULTY

#### Invited Course Faculty

**Arjun Balar, MD**  
Associate Professor of Medicine  
NYU Perlmutter Cancer Center

**James M. McKiernan, MD**  
Chairman, Urologist-in-Chief  
Department of Urology  
Columbia University/NewYork-Presbyterian

**Brian Shuch, MD**  
Associate Professor of Urology  
Department of Urology  
UCLA School of Medicine

**R. Houston Thompson, MD**  
Professor of Urology  
Department of Urology  
Mayo Clinic

#### Keynote Speaker

**Brian I. Rini, MD, FACP**  
Professor of Medicine  
Lerner College of Medicine Leader, GU Program  
Director, Experimental Therapeutics Fellowship Program  
Hematology and Oncology & Glickman Urological and Kidney Institute  
Cleveland Clinic Taussig Cancer Institute

### MSK Course Faculty

- **Oguz Akin, MD**  
  Attending Radiologist  
  Director of Body MRI  
  Department of Radiology

- **Hikmat Al-Ahmadie, MD**  
  Associate Attending Pathologist  
  Genitourinary Pathology

- **Charlotte E. Ariyan, MD, PhD**  
  Associate Attending Surgeon  
  Gastric and Mixed Tumor Service

- **Dean F. Bajorin, MD**  
  Attending Physician  
  Frederick R. Adler Senior Faculty Chair  
  Genitourinary Oncology Service  
  Professor of Medicine, Weill Cornell Medical College

- **Bernard H. Bochner, MD, FACS**  
  Attending Surgeon  
  Urology Service  
  Sir Murray Brennan Chair in Surgery

- **Eugene K. Cha, MD**  
  Assistant Attending Surgeon  
  Urology Service

- **Timothy A. Chan, MD, PhD**  
  Vice Chair and Attending Physician  
  Department of Radiation Oncology  
  Director, Division of Translational Oncology  
  Director, Immuno-oncogenomics and Precision Oncology Platform  
  Member, Human Oncology and Pathogenesis Program

- **Yingbei Chen, MD, PhD**  
  Associate Attending Pathologist  
  Genitourinary Pathology

- **Marie Carlo, MD**  
  Assistant Attending  
  Genitourinary Oncology Service

- **Jonathan A. Coleman, MD**  
  Associate Attending Surgeon  
  Urology Service

- **Timothy F. Donahue, MD**  
  Associate Attending Surgeon  
  Urology Service

- **S. Machele Donat, MD, FACS**  
  Attending Surgeon  
  Urology Service

- **Jeremy C. Durack, MD, MS**  
  Attending Radiologist  
  Interventional Radiology Service

- **James A. Eastham, MD, FACS**  
  Chief, Urology Service  
  Peter T. Scardino Chair in Oncology

- **Darren R. Feldman, MD**  
  Associate Attending  
  Genitourinary Oncology Service

- **Samuel A. Funt, MD**  
  Assistant Attending  
  Genitourinary Oncology Service

- **Alvin C. Goh, MD**  
  Associate Attending Surgeon  
  Urology Service

- **Abraham A. Hakimi, MD**  
  Assistant Attending Surgeon  
  Urology Service

- **Harry W. Herr, MD**  
  Attending Surgeon  
  Urology Service

- **Gopakumar V. Iyer, MD**  
  Assistant Attending  
  Bladder Cancer Section Head  
  Genitourinary Oncology Service

- **Marisa A. Kollmeier, MD**  
  Associate Attending Physician  
  Chair, Radiation Oncology Quality Assurance  
  Brachytherapy Service

- **Chung-Han Lee, MD, PhD**  
  Assistant Attending  
  Genitourinary Oncology Service

- **Robert J. Motzer, MD**  
  Attending  
  Genitourinary Oncology Service

- **Eugene Pietzak, MD**  
  Assistant Attending Surgeon  
  Urology Service  
  Brachytherapy Service

- **Paul Russo, MD**  
  Attending Surgeon  
  Urology Service  
  Professor of Urology, Weill Cornell College of Medicine

- **Jonathan E. Rosenberg, MD**  
  Chief, Genitourinary Medical Oncology Service  
  Division of Solid Tumor Oncology

- **R. Houston Thompson, MD**  
  Professor of Urology  
  Department of Urology  
  Mayo Clinic

- **Min Yuen Teo, MD**  
  Assistant Attending  
  Genitourinary Oncology Service

- **Martin H. Voss, MD**  
  Assistant Attending  
  Genitourinary Oncology Service

---

**Join the conversation:**  
#MSKurologyCME  
@MSKCME
Thursday, October 24

Lunch and Registration 12:00 PM

Bladder (Non-muscle Invasive Bladder Cancer)
Moderator: Timothy F. Donahue, MD
Updated on Natural History of High Risk NIMBC 1:00 PM
Bernard H. Bochner, MD, FACS
NMIBC Molecular Biology 1:15 PM
Eugene Pietzak, MD
New Detection Technologies: Blue Light and NBI 1:40 PM
James M. McKiernan, MD

Bladder (Non-muscle Invasive Bladder Cancer)
Moderator: Bernard H. Bochner, MD, FACS
Management of BCG - Unresponsive NMIBC 2:00 PM
Eugene K. Cha, MD
Role of Checkpoint Inhibitors for NMIBC 2:15 PM
Dean F. Bajorin, MD
Case Discussions 2:30 PM
BCG Shortage; Optimal BCG, Selection for Early Cystectomy; Persistent Positive Cytology (Natural History, Surveillance vs. Therapy)
Harry W. Herr, MD
Dean F. Bajorin, MD
Eugene K. Cha, MD
James M. McKiernan, MD
Break 3:00 PM

Kidney (Localized)
Moderator: Jonathan A. Coleman, MD
SRM – Epidemiology and Treatment Molecular (overtreatment) 3:10 PM
Abraham A. Hakimi, MD
Biopsy 3:25 PM
Yingbei Chen, MD, PhD
Ablation 3:40 PM
Jeremy C. Durack, MD, MS
Surveillance and Genomics 3:55 PM
Brian Shuch, MD

Break 4:00 PM

Bladder (Muscle Invasive Bladder Cancer)
Moderator: Gopakumar V. Iyer, MD
Neoadjuvant Therapy for Cis-eligible Patients (Cisplatin-based Chemotherapy, IO+Chemotherapy Trials) 4:10 PM
Gopakumar V. Iyer, MD
Adjuvant Therapy for MIBC (including data on standard and novel therapies) 4:25 PM
Min Yuen Teo, MD
Importance of Germline Mutations in Urothelial Cancer 4:40 PM
Marie Carlo, MD

Break 5:00 PM

Networking Reception
Course attendees are invited to join the faculty for a networking reception immediately following the conclusion of day one from 5:00-6:30 PM at Zuckerman Research center. Hors d’oeuvres and refreshments will be served.

Friday, October 25

Breakfast 7:30 AM

Keynote Address
Department of Medicine Grand Rounds
Moderator: Jonathan E. Rosenberg, MD
Emerging Paradigms in the Upfront Management of Metastatic Kidney Cancer 8:00 AM
Brian I. Rini, MD, FACP
Q&A 8:45 AM

Kidney (Locally Advanced)
Moderator: Abraham A. Hakimi, MD
Partial vs Radical for >= pT1b 9:15 AM
Paul Russo, MD
LN Dissection 9:30 AM
R. Houston Thompson, MD
Perioperative Therapy in the Non-metastatic Setting 9:45 AM
Martin H. Voss, MD
Q&A 10:05 AM

Kidney
Moderator: Abraham A. Hakimi, MD
Case Discussions 10:15 AM
Large Renal Masses, Node Positive, Solitary Kidney
Break 11:00 AM

Bladder (Robotics and Radical Cystectomy)
Moderator: Timothy F. Donahue, MD
Open vs Robotic Surgery for MIBC: Update of Current data 11:10 AM
Bernard H. Bochner, MD, FACS
RARC: How to. Tips and Tricks 11:25 AM
Alvin C. Goh, MD
Case Discussions 11:40 AM
Bernard H. Bochner, MD, FACS
Eugene K. Cha, MD
Alvin C. Goh, MD
Jonathan A. Coleman, MD
Lunch 12:00 PM
**Saturday, October 26**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td>Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td>Surgical Safety in IO Treated Patients</td>
<td>Charlotte E. Ariyan, MD, PhD</td>
</tr>
<tr>
<td>8:20</td>
<td>IO Tox Management</td>
<td>Samuel A. Funt, MD</td>
</tr>
<tr>
<td>9:00</td>
<td>Cytoreduction + Metastasectomy</td>
<td>Paul Russo, MD</td>
</tr>
<tr>
<td>9:40</td>
<td>Systemic Therapy for Metastatic ncRCC</td>
<td>Darren R. Feldman, MD</td>
</tr>
<tr>
<td>10:00</td>
<td>Emerging Regimens for Metastatic RCC</td>
<td>Chung-Han Lee, MD, PhD</td>
</tr>
<tr>
<td>10:30</td>
<td>Bladder (Muscle Invasive Bladder Cancer)</td>
<td>Dean F. Bajorin, MD</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>Risk Stratification and Molecular Classifiers in the Metastatic Setting</td>
<td>Gopakumar V. Iyer, MD</td>
</tr>
<tr>
<td>1:50 PM</td>
<td>Molecular Biology of MIBC - Role in Bladder Preservation</td>
<td>Gopakumar V. Iyer, MD</td>
</tr>
<tr>
<td>2:20 PM</td>
<td>Bladder Preservation</td>
<td>Marisa A. Kollmeier, MD</td>
</tr>
<tr>
<td>2:50 PM</td>
<td>Bladder (Upper Tract TCC and Bladder Variants)</td>
<td>Gopakumar V. Iyer, MD, Marisa A. Kollmeier, Harry W. Herr, MD</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Upper Tract TCC Molecular Differences and Clinical Management of UTCC</td>
<td>Jonathan A. Coleman, MD</td>
</tr>
<tr>
<td>3:20 PM</td>
<td>Histologic Variants of Bladder Cancer</td>
<td>Hikmat Al-Ahmadie, MD</td>
</tr>
<tr>
<td>3:35 PM</td>
<td>Bladder Preservation</td>
<td>Gopakumar V. Iyer, Marisa A. Kollmeier, Harry W. Herr, MD</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Clinical Management of Histologic Variants</td>
<td>Jonathan A. Coleman, MD</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>Clinical Management of Histologic Variants</td>
<td>Hikmat Al-Ahmadie, MD</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Case Discussions</td>
<td>Bernard H. Bochner, MD, FACS</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td>Symposium Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
REGISTRATION

<table>
<thead>
<tr>
<th>Registration Fees</th>
<th>Early*</th>
<th>General</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs &amp; DOs)</td>
<td>$500</td>
<td>$600</td>
</tr>
<tr>
<td>Advanced Practice Providers</td>
<td>$350</td>
<td>$450</td>
</tr>
<tr>
<td>Residents, Fellows, Nurses &amp; Other Healthcare Providers</td>
<td>$200</td>
<td>$300</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>$900</td>
<td>$1,100</td>
</tr>
<tr>
<td>Live Simulcast</td>
<td>--</td>
<td>$800</td>
</tr>
</tbody>
</table>

Register online: mskcc.org/urologycourse

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

- MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
- MSK employee registration is complimentary. However, you must complete course registration in order to attend this course.

*Early registration rates expire August 23, 2019.

**Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

ACCREDITATION

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMC Credit Designation Statement
Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty Disclosure
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Advances in the Management of Bladder and Kidney Cancer

A MULTIDISCIPLINARY APPROACH

Memorial Sloan Kettering Cancer Center